Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
Go back to Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin| (NASDAQ: RUBY) | Delayed: 0.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.08 | 52 Week High | $ | |||
| Open | $0.08 | 52 Week Low | $ | |||
| Day High | $0.08 | P/E | N/A | |||
| Day Low | $0.08 | EPS | $ | |||
| Volume | 266,532 | |||||
